Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
305 studies found for:    Open Studies | "Triplets"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Triplets"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Cisplatin vs Paclitaxel for Triple Neg
Condition: Triple Negative Breast Cancer
Interventions: Drug: Cisplatin;   Drug: Paclitaxel
2 Recruiting Patient-derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast Cancer
Condition: Triple Negative Breast Cancer
Intervention: Other: Chemotherapy
3 Not yet recruiting Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer
Condition: Triple-negative Breast Cancer
Interventions: Drug: IMMU-132 infusion is administered to participants in one arm for the study;   Drug: IMMU-132 plus Carboplatin infusion
4 Recruiting Comparison of Biological Features Between pN0 Triple Negative Breast Tumours With Size < or = 10 mm (pT1a/b) Versus pT1c T2 < or = 30 mm
Condition: Triple Negative Breast Cancers Without Lymph-node Involvement and < or = 30 mm
Intervention: Procedure: Blood samples of 10 mL
5 Recruiting Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE 173)
Condition: Triple Negative Breast Neoplasms
Interventions: Biological: Pembrolizumab;   Drug: Nab-paclitaxel;   Drug: Anthracycline (doxorubicin);   Drug: Cyclophosphamide;   Drug: Carboplatin;   Drug: Paclitaxel
6 Recruiting Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity
Condition: Triple Negative Breast Neoplasms
Interventions: Drug: Docetaxel;   Drug: Carboplatin
7 Recruiting Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer
Condition: Triple Negative Breast Cancer
Interventions: Drug: Pembrolizumab;   Drug: Cyclophosphamide
8 Recruiting Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer
Condition: Triple-negative Breast Cancer
Interventions: Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Docetaxel
9 Recruiting Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer
Condition: Metastatic Triple Negative Breast Cancer
Intervention: Drug: Combination of Veliparib + Lapatinib
10 Recruiting Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
Condition: Triple Negative Breast Cancer
Intervention: Drug: GTx-024
11 Recruiting Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab: A Phase III Randomized Trial
Condition: Triple Negative Breast Neoplasms
Intervention: Drug: MSB0010718C
12 Not yet recruiting Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer
Condition: Triple Negative Breast Cancer
Interventions: Drug: Drug: Selumetinib;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Docetaxel
13 Recruiting L-NMMA Plus Docetaxel in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients
Condition: Metastatic Triple Negative Breast Cancer
Interventions: Drug: L-NMMA;   Drug: Docetaxel;   Drug: Amlodipine;   Drug: Pegfilgrastim
14 Recruiting Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer
Condition: Metastatic gpNMB Over-expressing Triple Negative Breast Cancer
Interventions: Drug: CDX-011;   Drug: Capecitabine
15 Recruiting Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)
Condition: Metastatic Triple Negative Breast Cancer
Interventions: Biological: pembrolizumab;   Drug: capecitabine;   Drug: eribulin;   Drug: gemcitaine;   Drug: vinorelbine
16 Recruiting Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)
Condition: Triple Negative Breast Cancer (TNBC)
Interventions: Biological: Pembrolizumab;   Drug: Nab-paclitaxel;   Drug: Paclitaxel;   Drug: Gemcitabine;   Drug: Carboplatin;   Drug: Normale Saline Solution
17 Recruiting Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)
Condition: Advanced Triple Negative Breast Cancer (TNBC) With High TAMs
Interventions: Drug: MCS110;   Drug: carboplatin;   Drug: gemcitabine
18 Recruiting Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy
Condition: Locally Recurrent/Metastatic Triple Negative Breast Cancer
Interventions: Radiation: external beam radiation therapy;   Drug: cisplatin;   Procedure: Biopsy of Target Tumor
19 Recruiting A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple Negative Breast Cancer (IMpassion130)
Condition: Metastatic Breast Cancer, Triple Negative Breast Cancer
Interventions: Drug: Atezolizumab [TECENTRIQ];   Drug: Nab-Paclitaxel;   Drug: Placebo
20 Not yet recruiting Safety and Efficacy Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
Condition: Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer
Intervention: Drug: OTS167PO

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.